358 related articles for article (PubMed ID: 34263692)
1. Targeting the spectrum of immune checkpoints in prostate cancer.
Sena LA; Denmeade SR; Antonarakis ES
Expert Rev Clin Pharmacol; 2021 Oct; 14(10):1253-1266. PubMed ID: 34263692
[No Abstract] [Full Text] [Related]
2. Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 1: Prostate Cancer Vaccines.
Patel A; Fong L
Oncology (Williston Park); 2018 Mar; 32(3):112-20. PubMed ID: 29548065
[TBL] [Abstract][Full Text] [Related]
3. An overview of sipuleucel-T: autologous cellular immunotherapy for prostate cancer.
Wesley JD; Whitmore J; Trager J; Sheikh N
Hum Vaccin Immunother; 2012 Apr; 8(4):520-7. PubMed ID: 22370520
[TBL] [Abstract][Full Text] [Related]
4. Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy.
Antonarakis ES; Drake CG
Curr Opin Oncol; 2012 May; 24(3):258-65. PubMed ID: 22410456
[TBL] [Abstract][Full Text] [Related]
5. Cancer immunotherapy: sipuleucel-T and beyond.
Hammerstrom AE; Cauley DH; Atkinson BJ; Sharma P
Pharmacotherapy; 2011 Aug; 31(8):813-28. PubMed ID: 21923608
[TBL] [Abstract][Full Text] [Related]
6. Beyond sipuleucel-T: immune approaches to treating prostate cancer.
Cheng ML; Fong L
Curr Treat Options Oncol; 2014 Mar; 15(1):115-26. PubMed ID: 24402184
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in immunotherapy for the treatment of prostate cancer.
Sonpavde G; Agarwal N; Choueiri TK; Kantoff PW
Expert Opin Biol Ther; 2011 Aug; 11(8):997-1009. PubMed ID: 21675925
[TBL] [Abstract][Full Text] [Related]
8. Combining immunotherapies for the treatment of prostate cancer.
Redman JM; Gulley JL; Madan RA
Urol Oncol; 2017 Dec; 35(12):694-700. PubMed ID: 29146441
[TBL] [Abstract][Full Text] [Related]
9. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
[TBL] [Abstract][Full Text] [Related]
10. Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer.
Gardner TA; Elzey BD; Hahn NM
Hum Vaccin Immunother; 2012 Apr; 8(4):534-9. PubMed ID: 22832254
[TBL] [Abstract][Full Text] [Related]
11. Molecular insights into the development of T cell-based immunotherapy for prostate cancer.
Dong B; Minze LJ; Xue W; Chen W
Expert Rev Clin Immunol; 2014 Nov; 10(11):1547-57. PubMed ID: 25259804
[TBL] [Abstract][Full Text] [Related]
12. Sipuleucel-T and immunotherapy in the treatment of prostate cancer.
Dawson NA; Roesch EE
Expert Opin Biol Ther; 2014 May; 14(5):709-19. PubMed ID: 24620782
[TBL] [Abstract][Full Text] [Related]
13. Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial.
Antonarakis ES; Kibel AS; Yu EY; Karsh LI; Elfiky A; Shore ND; Vogelzang NJ; Corman JM; Millard FE; Maher JC; Chang NN; DeVries T; Sheikh NA; Drake CG;
Clin Cancer Res; 2017 May; 23(10):2451-2459. PubMed ID: 27836866
[No Abstract] [Full Text] [Related]
14. Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?
Laccetti AL; Subudhi SK
Curr Opin Urol; 2017 Nov; 27(6):566-571. PubMed ID: 28825923
[TBL] [Abstract][Full Text] [Related]
15. Prostate Cancer Immunotherapy-Finally in From the Cold?
Runcie KD; Dallos MC
Curr Oncol Rep; 2021 Jun; 23(8):88. PubMed ID: 34125308
[TBL] [Abstract][Full Text] [Related]
16. Strategies for optimizing the clinical impact of immunotherapeutic agents such as sipuleucel-T in prostate cancer.
Madan RA; Schwaab T; Gulley JL
J Natl Compr Canc Netw; 2012 Dec; 10(12):1505-12. PubMed ID: 23221788
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks.
Comiskey MC; Dallos MC; Drake CG
Curr Oncol Rep; 2018 Aug; 20(9):75. PubMed ID: 30120592
[TBL] [Abstract][Full Text] [Related]
18. Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges.
Paller CJ; Antonarakis ES
Hum Vaccin Immunother; 2012 Apr; 8(4):509-19. PubMed ID: 22336881
[TBL] [Abstract][Full Text] [Related]
19. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.
McKarney I
Issues Emerg Health Technol; 2007 Sep; (101):1-4. PubMed ID: 17763575
[TBL] [Abstract][Full Text] [Related]
20. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.
Sims RB
Vaccine; 2012 Jun; 30(29):4394-7. PubMed ID: 22122856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]